Cagrilintide is a long-acting synthetic analogue of amylin, a naturally occurring peptide hormone involved in appetite, satiety and metabolic signalling. Researchers study Cagrilintide for its effects on amylin-receptor activity, food-intake regulation, feelings of fullness, body-weight regulation and interactions with other metabolic pathways.
Research includes laboratory studies as well as human clinical trials investigating Cagrilintide alone and in combination with semaglutide. Although clinical research has reported measurable effects on appetite and body weight, study results relate to specifically manufactured investigational drug products and controlled clinical protocols and cannot be transferred automatically to independently supplied research material. This material is intended for laboratory research only, is not authorized by Health Canada for human therapeutic use, and is not intended for human or veterinary administration.
Choose a kit option to save more, or skip this and buy individually above.
*LC-MS identity confirmation may be performed when analytical review indicates conflicting, atypical, or inconclusive results.
Cagrilintide is a modified analogue of human amylin, a peptide hormone normally produced by pancreatic beta cells and released together with insulin following food intake. Natural amylin participates in several processes associated with meal regulation, including communication between the digestive system and regions of the brain involved in appetite and satiety.
Unlike naturally occurring amylin, Cagrilintide has been deliberately modified to provide greater molecular stability and a substantially longer duration of activity. Its structure contains several amino-acid substitutions designed partly to reduce the tendency of human amylin to aggregate or form fibrils. It also contains a lipid modification involving a C20 fatty diacid that promotes reversible association with albumin and contributes to prolonged exposure.
This long-acting design has made Cagrilintide useful for research examining sustained amylin-receptor signalling rather than only the short-lived activity associated with native amylin.
Amylin is part of the body's system for communicating that food has been consumed. After a meal, pancreatic beta cells release both insulin and amylin. While insulin is primarily associated with glucose regulation, amylin contributes additional signals involving appetite, meal size and digestive activity.
Amylin receptors are found in several areas involved in metabolic regulation. They are formed when the calcitonin receptor interacts with proteins known as receptor activity-modifying proteins, or RAMPs. This creates several related amylin-receptor subtypes.
When these receptors are activated, signals can reach regions of the nervous system involved in determining whether additional food intake is required. Researchers therefore study amylin analogues to understand how this pathway influences hunger, satiety, meal termination and overall energy intake.
Cagrilintide was designed to maintain this type of biological activity for much longer than native amylin. Structural research has demonstrated its interaction with amylin receptors and helped clarify how its modified peptide structure engages these receptor systems.
Cagrilintide has progressed through several levels of research, each answering different scientific questions:
These categories should not be treated as interchangeable. Receptor activity demonstrates that a compound can interact with a biological target, while clinical studies investigate what happens in people under a defined pharmaceutical formulation, dose and protocol.
Likewise, results from an investigational Cagrilintide formulation manufactured for a clinical trial do not establish the safety, effectiveness or suitability of independently manufactured research material.
One of the principal areas of Cagrilintide research involves appetite and satiety.
Satiety refers to the sensation of having consumed enough food and the reduction in motivation to continue eating. Amylin is one of several biological signals contributing to this process. By producing prolonged amylin-receptor activity, Cagrilintide allows researchers to investigate what happens when this signalling pathway remains active for an extended period.
The research is particularly interesting because appetite is controlled by multiple interacting pathways rather than a single hormone. Hunger signals, gastrointestinal signals, nutrient sensing, central nervous system activity and learned behaviour all contribute to food intake.
Cagrilintide therefore does not simply represent another version of a GLP-1 compound. It investigates a different metabolic signalling pathway that can influence some overlapping outcomes, including appetite and energy intake.
Human clinical research has provided evidence that sustained Cagrilintide exposure can influence body-weight outcomes, including dose-dependent effects observed in a randomized phase 2 trial. These findings support continued investigation but apply to the specific pharmaceutical material, doses and study populations that were evaluated.
Because appetite and energy intake are closely connected with body-weight regulation, Cagrilintide has become an important experimental compound in obesity and metabolic research.
Researchers are interested in whether prolonged amylin signalling can reduce energy intake sufficiently to produce sustained changes in body weight. Clinical programs have therefore measured changes in body weight over many months rather than relying only on short-term appetite measurements.
Later clinical development has included both Cagrilintide monotherapy and combination research. Novo Nordisk has advanced Cagrilintide into its phase 3 RENEW development program, including studies investigating Cagrilintide in populations with and without type 2 diabetes.
This represents substantially more human evidence than exists for many experimental metabolic compounds. It does not, however, mean that every material labelled Cagrilintide is equivalent to the investigational pharmaceutical product used in those trials.
Manufacturing quality, chemical identity, concentration, formulation, impurities, sterility and stability can materially affect a research material and must be evaluated separately.
One of the most significant areas of Cagrilintide research involves combining amylin signalling with GLP-1 receptor signalling.
GLP-1 and amylin influence appetite through different but partially complementary biological pathways. Researchers have therefore investigated whether simultaneously targeting both systems could provide broader effects on appetite, energy intake and metabolic regulation.
Cagrilintide has been extensively studied alongside semaglutide in a combination commonly referred to during clinical development as CagriSema.
Large phase 3 trials have evaluated the combination in people with overweight or obesity, both with and without type 2 diabetes. In the REDEFINE 2 trial, for example, Cagrilintide and semaglutide were investigated together for 68 weeks in adults with overweight or obesity and type 2 diabetes. The study reported significantly greater body-weight reduction with the combination than with placebo, while gastrointestinal adverse events were common and were generally reported as transient and mild to moderate.
The combination research is scientifically important because it demonstrates how separate metabolic pathways may be investigated together. It should not be interpreted as evidence that separately sourced research compounds will reproduce a pharmaceutical combination product.
Cagrilintide is substantially more than native amylin placed into a vial.
Human amylin has characteristics that make pharmaceutical development difficult, including a tendency to aggregate and form fibrils. Researchers developing Cagrilintide introduced several amino-acid substitutions intended to improve its physicochemical properties while retaining receptor activity.
The molecule also incorporates a fatty-acid modification. A C20 fatty diacid is attached through a linker to the peptide, increasing reversible interaction with albumin. Albumin association can reduce rapid clearance and is an established strategy for extending the biological exposure of certain peptide compounds.
Cagrilintide also retains structural features important to amylin-receptor activity, including a disulfide bridge near the N-terminus and a C-terminal amide. Published medicinal-chemistry research describes how these structural features and amino-acid substitutions were systematically evaluated during development.
The result is a modified long-acting amylin analogue rather than an identical copy of naturally occurring human amylin.
Unlike compounds supported almost entirely by cell or animal experiments, Cagrilintide has been investigated directly in human clinical studies.
This provides researchers with meaningful information about how pharmacological amylin-receptor activation may affect appetite regulation and body weight in defined populations.
However, an important distinction remains between evidence for the molecule being investigated as a pharmaceutical candidate and evidence concerning an individual research product.
Clinical trials use investigational products manufactured according to tightly controlled pharmaceutical specifications. Purity, concentration, formulation, stability, microbiology and manufacturing conditions are controlled independently of the molecular identity printed on the label.
A research vial confirmed as containing Cagrilintide by LC-MS does not automatically become equivalent to the investigational product evaluated during a clinical trial.
Human clinical evidence therefore establishes important information about the biological and pharmacological potential of Cagrilintide, while batch-specific analytical testing establishes what is actually contained in a particular research sample. Those are related but separate questions.
Several limitations should remain clear when interpreting Cagrilintide research:
Analytical claims should also remain separate. HPLC can provide information about chromatographic purity. Mass spectrometry can support molecular identity. A validated quantitative assay can measure active content. Sterility and endotoxin testing require separate methods.
One analytical result should not be presented as though it establishes every property of the product.
Cagrilintide remains an investigational metabolic compound undergoing clinical development.
Novo Nordisk has advanced Cagrilintide monotherapy into phase 3 development, while Cagrilintide combined with semaglutide has also undergone large phase 3 trials.
In Canada, Health Canada currently lists cagrilintide with semaglutide as a new-active-substance drug submission under review, with the submission listed from March 2026. A submission under review is not the same as market authorization.
The material described on this page is supplied independently as a laboratory research material. It is not a pharmaceutical dosage form, licensed prescription drug or authorized injectable product.
No human dosage, administration schedule, reconstitution instructions or treatment protocol is provided.
For laboratory research only. Not for human or veterinary use.
Cagrilintide is a synthetic, long-acting analogue of human amylin containing amino-acid modifications and a lipid component designed to extend biological exposure. The molecule maintains structural characteristics required for amylin-receptor activity while incorporating modifications intended to improve stability and pharmacokinetic behaviour.
PubChem lists Cagrilintide under CAS 1415456-99-3 with molecular formula C₁₉₄H₃₁₂N₅₄O₅₉S₂ and a computed molecular weight of approximately 4409 g/mol.
Cagrilintide is based on the human-amylin peptide framework but contains multiple structural modifications.
The peptide backbone contains 37 amino-acid residues and includes substitutions selected during development to reduce fibrillation, improve physicochemical stability and retain amylin-receptor activity.
A representative backbone sequence is:
KCNTATCATQRLAEFLRHSSNNFGPILPPTNVGSNTP
The complete molecule cannot be described accurately by the amino-acid sequence alone because Cagrilintide also includes lipid modification and terminal structural features.
Important structural characteristics include:
Published structural and medicinal-chemistry research shows that these modifications contribute to the distinction between Cagrilintide and naturally occurring human amylin.
The complete modified molecule, rather than the peptide sequence alone, should therefore be used when assessing identity by appropriate analytical methods.
The term lyophilized should be used only when freeze-drying is confirmed by manufacturing or product documentation. Appearance alone cannot confirm Cagrilintide identity, purity, active quantity, sterility or endotoxin status.
Representative analytical certificates for Cagrilintide research material describe white or white-to-off-white lyophilized material, but physical appearance remains a batch characteristic rather than an identity test.
Chromatographic purity: High-performance liquid chromatography, UPLC or LC-MS-associated chromatography may be used to separate the principal Cagrilintide-related component from detectable peptide-related impurities.
An HPLC purity percentage normally represents the relative chromatographic area associated with the principal peak under the specified analytical method. It should not be interpreted automatically as the percentage of active Cagrilintide by total vial weight.
Chromatographic purity does not independently determine:
Identity assessment: Mass spectrometry can support molecular identification by comparing measured ions with those expected from Cagrilintide's molecular structure.
Because Cagrilintide has a molecular mass of approximately 4409 Da, electrospray mass spectrometry commonly produces multiply charged ions rather than only a single molecular ion. Interpretation should therefore consider charge state, adduct formation and the analytical method used.
Quantitative content: Determining the amount of Cagrilintide in a vial requires an appropriate quantitative method or qualified reference standard. Gross lyophilized powder weight cannot establish peptide quantity because freeze-dried preparations may contain water, buffers, counterions or other formulation components.
Depending on the research application, analytical characterization may include:
Only testing actually completed on the applicable batch should be represented as a verified product attribute.
The currently identified Cagrilintide research material is labelled:
Batch-specific analytical values should be added only after corresponding laboratory documentation is available.
Until verified by the applicable Certificate of Analysis, the following should not be assumed:
If independent analysis is completed, each result should be presented according to the test actually performed. Identity, chromatographic purity, net content, sterility and endotoxin testing are different measurements and should not be combined into a single general claim such as “lab tested.”
Keep unopened research material in its original sealed container and protect it from unnecessary exposure to light, moisture and repeated temperature changes.
Exact storage temperature and validated shelf life should be based on manufacturer documentation, batch-specific stability information or an appropriate experimental protocol.
General laboratory considerations include:
Published development research indicates that Cagrilintide's stability and solubility can be influenced by formulation conditions, including pH. Storage and handling specifications should therefore be based on the characterized material rather than generalized from the peptide name alone.
This product is supplied exclusively as a laboratory research material.
It is not manufactured, represented or released as a licensed prescription drug, sterile injectable preparation, food, dietary supplement, natural health product or veterinary pharmaceutical.
It is not intended for:
No human dosage, administration schedule, reconstitution procedure or treatment protocol is provided.
Published clinical studies involving Cagrilintide concern specifically manufactured investigational pharmaceutical products used under controlled clinical protocols. Those findings do not establish that independently supplied research material is suitable for human administration.
Health Canada currently lists a Cagrilintide/semaglutide new drug submission as under review rather than as an authorized product.
For laboratory research only. Not for human or veterinary use.
These specifications describe the general molecular identity, physical characteristics, analytical considerations, research status and intended laboratory classification of Cagrilintide.
Final product information should be based on the Certificate of Analysis and supporting documentation for the specific batch being supplied.
Where general reference information and batch-specific analytical documentation differ, the discrepancy should be investigated before publication.
A Certificate of Analysis applies only to the sample and analyses described in that document. It does not by itself establish:
Molecular identity, chromatographic purity, measured peptide quantity, water content, sterility and endotoxin status are separate analytical characteristics and should be reported independently.
Additional documentation available upon request.
Each batch undergoes analytical review using validated laboratory procedures. HPLC testing is utilized to assess purity and compare the sample profile against established reference standards. Where additional verification is warranted, LC-MS analysis may be performed to support compound identity confirmation.
*See LC-MS Confirmation Information for full details.
Every batch supplied by Vanguard Compound Research is assigned a unique batch number and maintained under documented quality-control procedures with supporting analytical documentation available upon request.
All Vanguard Compound Research orders are shipped directly from within Canada, ensuring efficient delivery, reliable service, and consistent quality-control from fulfillment to arrival.
Products are maintained under documented quality-control procedures to help ensure quality, consistency, and transparency.
Each product is assigned a unique lot number, allowing researchers to match their item directly to its corresponding Certificate of Analysis (COA).
Supporting analytical documentation may be available for qualifying products, including batch-specific quality records and testing information.
Documentation may include: